Literature DB >> 8827127

Haemophilia and HIV infection in Hong Kong.

S S Lee1, K H Wong, A J Dickinson.   

Abstract

This is a retrospective study of the problems faced and support received by HIV (human immunodeficiency virus) infected haemophilia patients in Hong Kong. Between December 1984 and December 1994, 63 patients were detected to be HIV positive, out of a total of 231 haemophiliacs screened. Infection could be traced back to before August 1985, when safer heat-treated clotting factors were not yet available. Psychosocial impacts were obvious in this group of patients because of the double blow of HIV infection and haemophilia. Amongst the more evident problems were obstacles in schooling, employment difficulties, and disturbed relationships with family and friends, to mention a few. Psychosocial support services have been rendered by both the government and non-governmental organizations in Hong Kong. Financial assistance has also been given by the government since April 1993. To date, only eleven (17.5%) patients were known to have progressed to AIDS. Medical treatment, psychosocial support and financial assistance are integral components of an effective AIDS care programme for HIV-infected haemophilia patients.

Entities:  

Keywords:  Acquired Immunodeficiency Syndrome; Asia; Behavior; Biology; Blood Coagulation Effects; Delivery Of Health Care; Developing Countries; Diseases; Eastern Asia; Economic Factors; Financial Activities; Financing, Government; Health; Hematological Effects; Hemic System; Hiv Infections; Hong Kong; Physiology; Psychosocial Factors; Research Report; Viral Diseases

Mesh:

Year:  1996        PMID: 8827127     DOI: 10.1080/09540129650125777

Source DB:  PubMed          Journal:  AIDS Care        ISSN: 0954-0121


  1 in total

1.  Hepatitis C virus infection in adult Chinese hemophilia patients negative for the human immunodeficiency virus: treatment results with interferon and ribavirin.

Authors:  Wing Y Au; Clarence C K Lam; Chi-Leung Liu; Man-Fung Yuen
Journal:  Int J Hematol       Date:  2005-10       Impact factor: 2.490

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.